Skip to content
Screener

Entrada Therapeutics TRDA Q2 2026 earnings

Reported August 5, 2026 · Before market open

Revenue$898.0KMiss by $1.4M
EPS-$1.01Miss by $0.04
Revenue estimate$2.3M
EPS estimate-$0.97

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.1M
EPS estimate-$0.98

FAQ

When did Entrada Therapeutics report Q2 2026 earnings?
Entrada Therapeutics (TRDA) reported Q2 2026 earnings on August 5, 2026 before market open.
What were Entrada Therapeutics's Q2 2026 revenue and EPS?
Entrada Therapeutics reported revenue of $898.0K and eps of $-1.01 for Q2 2026.
Did Entrada Therapeutics beat estimates in Q2 2026?
Revenue missed the consensus estimate of $2.3M by $1.4M. EPS missed the consensus estimate of $-0.97 by $0.04.
How did Entrada Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 53.9% from $2.0M a year earlier and eps grew 2.9% from $-1.04.
Where can I find Entrada Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001689375-26-000052) and the 10-Q periodic report (0001689375-26-000054) directly on SEC EDGAR. The filing index links above go to sec.gov.